ASIT Biotech To Disclose The Detailed Results Of Its Phase III Clinical Study With gp-ASIT+ For The Treatment Of Grass Pollen Rhinoconjunctivitis At EAACI 2017
Published: May 31, 2017
BRUSSELS--(BUSINESS WIRE)--Regulatory News:
ASIT biotech (Euronext: ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, is proud to have the opportunity to present two late-breaking communications on the detailed results of its phase III clinical study with gp-ASIT+™, its product candidate for the treatment of grass pollen rhinoconjunctivitis, at the European Academy of Allergy and Clinical Immunology (EAACI) congress in Helsinki, June 17-21, 2017.
EAACI is the most important event of the Academy, and is one of the biggest international meetings dedicated to Allergology and Clinical Immunology. It gathers thousands of delegates from all around the world, and offers simultaneous sessions covering all aspects of the Academy’s specialty.
The two ASIT biotech’s late-breaking abstracts have been selected by the EAACI review committee:
Title: Efficacy of a 3-week subcutaneous immunotherapy course in
patients with grass pollen-induced rhinoconjunctivitis: Results of a
Presenter: Pr. Dr. Ralph Mösges (University of Köln)
Session: LB PDS 4 Allergen immunotherapy: Vaccines and clinical – June 19, 2017 – 10:45 am
Session type: Poster discussion
Title: Short Course treatment of Subcutaneous Peptide Hydrolysate
from Lolium Perenne suppresses Basophil Responses and induces
IgG-associated Blocking Antibodies: A Randomized Double-Blind
Presenter: Dr. Mohamed Shamji (Imperial College of London)
Session: LB OAS 5 Allergen Immunotherapy – mechanisms and vaccines – June 21, 2017 – 10:30 am
Session type: Oral presentation
About ASIT biotech
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.
ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at: www.asitbiotech.com.
Forward Looking Statements
All statements in this announcement that do not relate to historical facts and events are “forward-looking statements”. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” “plans,” “continue,” “ongoing,” “potential,” “predict,” “project,” “target,” “seek” or “should” or, in each case, their negative or other variations or comparable terminology or by discussions of strategies, plans, objectives, targets, goals, future events or intentions. Forward-looking statements include statements regarding the Company’s intentions, beliefs or current expectations. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. Given these risks and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. Any forward-looking statements are made only as of the date of this announcement and, without prejudice to the Company’s obligations under applicable law in relation to disclosure and ongoing information, the Company does not intend, and does not assume any obligation, to update the forward-looking statements set forth in this announcement.
Important Legal Notice
This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for shares of ASIT biotech SA (the “Company” and the “Shares”). Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be. This announcement does not constitute a prospectus and the information contained herein is for information purposes only and does not purport to be full or complete. Investors should not subscribe for any Shares except on the basis of the information contained in the prospectus that the Company expects to publish after its approval by the Belgian Financial Services and Markets Authority, and which can then be obtained at the Company’s registered office and on www.asitbiotech.com.
This announcement is not for distribution, directly or indirectly, in or into the United States or to any U.S. person within the meaning of the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been and will not be registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. The Company has not registered, and does not intend to register, any portion of the intended offering of Shares in the United States, and does not intend to conduct a public offering of Shares in the United States.
This announcement and the information contained herein are not for publication, distribution or release in or into the United States, Australia, Canada, Japan or any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.
The Company is responsible for the information contained in this press release.
Thierry Legon, CEO
Tel. +32 2 264 03 90
Media and Investor Relations - France
Dusan Oresansky / Pierre Laurent
Tel.: +33 1 44 71 94 92
Media Relations - Belgium
Tel.: +32 2 290 90 93